United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

Posted by Stanley Muller on Oct 15th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $550.70, for a total transaction of $5,231,650.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $178,670,760.10. This trade represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

United Therapeutics Stock Performance

UTHR stock opened at $540.03 on Thursday. The stock has a market capitalization of $23.16 billion, a P/E ratio of 19.32, a PEG ratio of 3.89 and a beta of 0.49. United Therapeutics Corporation has a one year low of $409.07 and a one year high of $609.35. The company has a 50 day moving average price of $513.58 and a two-hundred day moving average price of $540.32.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the prior year, the company posted $6.41 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Bank of America reduced their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Jefferies Financial Group reissued a “buy” rating and issued a $728.00 price target on shares of United Therapeutics in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Royal Bank Of Canada lifted their price target on United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Finally, The Goldman Sachs Group initiated coverage on shares of United Therapeutics in a research note on Thursday, September 24th. They set a “sell” rating and a $321.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $639.08.

Check Out Our Latest Analysis on United Therapeutics

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently bought and sold shares of UTHR. Callan Family Office LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $1,217,000. Andra AP fonden lifted its stake in shares of United Therapeutics by 33.5% in the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after acquiring an additional 8,760 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of United Therapeutics in the second quarter worth about $3,359,000. Seven Fleet Capital Management LP acquired a new position in shares of United Therapeutics in the fourth quarter worth about $633,000. Finally, Partners Capital Investment Group LLP purchased a new position in United Therapeutics in the second quarter valued at about $1,691,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: United Therapeutics reached a global settlement resolving all six pending lawsuits with Liquidia. The agreement eliminates significant patent and antitrust uncertainty and should reduce future legal expenses. United Therapeutics Reaches Major Pulmonary Hypertension Settlement
Positive Sentiment: The settlement is financially favorable in the near term because Liquidia will make payments totaling approximately $380.7 million. It also preserves United Therapeutics’ ability to compete in pulmonary arterial hypertension while bringing greater clarity to the market. LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Positive Sentiment: Jefferies raised its price target for UTHR to $728, while the broader analyst consensus remains favorable, with an average target near $627 and most analysts rating the stock Buy or Overweight. United Therapeutics Price Target Raised to $728
Neutral Sentiment: The latest quarterly results showed stronger-than-expected adjusted earnings, but revenue missed estimates and declined year over year. This mixed operating backdrop may be limiting enthusiasm despite the legal resolution.
Negative Sentiment: By settling, United Therapeutics allows Liquidia’s YUTREPIA to remain available for PAH patients. That could increase competition with Tyvaso and other United Therapeutics products, although the settlement reportedly imposes limitations on YUTREPIA’s labeling and does not provide unrestricted access to every indication. What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring
Negative Sentiment: CEO Martine Rothblatt disclosed sales of 9,500 UTHR shares, worth roughly $5.2 million. The transaction is relatively small compared with her remaining stake but may add modest sentiment pressure. United Therapeutics CEO Stock Sale

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.